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The neuropeptide Pituitary adenylate cyclase-activating polypeptide (PACAP) is
well-known for its important functions in immunity and inflammation. Data regarding
anti-inflammatory properties of PACAP in the intestinal tract are limited, however. In
our present preclinical intervention study we addressed whether PACAP treatment
could alleviate experimental subacute ileitis mimicking human gut microbiota conditions.
Therefore, secondary abioitic mice were subjected to human fecal microbiota
transplantation (FMT) and perorally infected with low-dose Toxoplasma gondii to induce
subacute ileitis on day 0. From day 3 until day 8 post-infection, mice were either treated
with synthetic PACAP38 or placebo. At day 9 post-infection, placebo, but not PACAP
treated mice exhibited overt macroscopic sequelae of intestinal immunopathology.
PACAP treatment further resulted in less distinct apoptotic responses in ileal and colonic
epithelia that were accompanied by lower T cell numbers in the mucosa and lamina
propria and less secretion of pro-inflammatory cytokines in intestinal ex vivo biopsies.
Notably, ileitis-associated gut microbiota shifts were less distinct in PACAP as compared
to placebo treated mice. Inflammation-ameliorating effects of PACAP were not restricted
to the intestines, but could also be observed in extra-intestinal including systemic
compartments as indicated by lower apoptotic cell counts and less pro-inflammatory
cytokine secretion in liver and lungs taken from PACAP treated as compared to placebo
control mice, which also held true for markedly lower serum TNF and IL-6 concentrations
in the former as compared to the latter. Our preclinical intervention study provides strong
evidence that synthetic PACAP alleviates subacute ileitis and extra-intestinal including
systemic sequelae of T cell-driven immunopathology. These findings further support
PACAP as a novel treatment option for intestinal inflammation including inflammatory
bowel diseases (IBD).
Keywords: pituitary adenylate cyclase-activating polypeptide (PACAP), subacute ileitis, Th1-type
immunopathology, human fecal microbiota transplantation, gut-brain axis, preclinical intervention study
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INTRODUCTION
The Pituitary adenylate cyclase-activating polypeptide (PACAP)
could be first identified in the hypothalamus exerting adenylate
cyclase stimulating activity within the pituitary gland (1). Being
part of the vasoactive intestinal peptide (VIP)/secretin/glucagon
family, the neuropeptide shares 68% sequence homology with
VIP and presents with two biologically active amidated forms
(i.e., PACAP 27 and PACAP38) after alternative splicing from
its pre-pro precursor (1, 2). Beyond the nervous system, PACAP
expression can be found in many peripheral organs within
the reproductive, respiratory, endocrine and digestive system
as well as in lymphoid compartments including immune cells
(2). PACAP is able to bind to VPAC1, VPAC2, and PAC1
receptors on innate immune cells including macrophages and
lymphocytes (3–5). Given its virtual ubiquitous expression,
PACAP presents with a variety of cyto-protective properties
including anti-inflammatory and anti-apoptotic effects (5, 6).
In experimental models of encephalomyelitis and arthritis, for
instance, distinct anti-inflammatory effects following exogenous
PACAP application have been demonstrated (7, 8). Data
regarding inflammation-ameliorating properties of synthetic
PACAP in the gastrointestinal tract are limited, however.
PACAP−/− mice suffered from more severe acute colitis
following dextran sodium sulfate (DSS) challenge as compared
to wildtype counterparts (9, 10).
Human inflammatory bowel diseases (IBD) such as Crohn’s
disease and ulcerative colitis comprise chronic inflammatory
conditions with acute episodes within the gastrointestinal tract
and are of multi-factorial etiology (11–13). Most in vivo studies
mimicking human IBD have applied experimental models of
the large intestines so far, whereas, however, small intestinal
inflammation models are rather scarce (14).
In our previous studies we applied an acute ileitis model
characterized by a severe T cell-driven immunopathology with
a lethal outcome within 1 week after peroral high-dose (i.e., >50
cysts) Toxoplasma gondii infection of mice (14–17). This high-
dose T. gondii infection model mimics key features of the acute
phase of human Crohn’s disease (“ileitis terminalis”), given (i)
the predilection site of the terminal ileum, (ii) the underlying
T helper cell (Th)−1 immunopathology that is (iii) associated
with marked shifts in gut microbiota composition (dysbiosis)
toward Gram-negative gut commensals, (iv) further contributing
to an acceleration of the inflammatory scenario via Toll-like
receptor (TLR)−4 dependent signaling of lipopolysaccharide
(LPS) derived from the Gram-negative commensal bacterial cell
walls (14). We were able to show that treatment of mice with
synthetic PACAP could efficiently ameliorate acute ileitis and
even extra-intestinal sequelae of T. gondii infection in a time-
of-treatment dependent fashion with highest efficacy during a
prophylactic regimen when starting PACAP application prior
ileitis induction (17). The within 1 week lethal outcome of the
hyper-acute inflammatory scenario following high-dose T. gondii
infection needs to be considered as a limitation of the applied gut
inflammation model, however.
This prompted us to unravel potential immune-modulatory
properties of PACAP during small intestinal inflammation of
less acute severity. Since the host specific gut microbiota is
known to be essentially involved in the onset, progress, and
outcome of distinct immunopathological conditions including
intestinal inflammation (15, 18, 19), we generated (with respect
to their gut microbiota) “humanized” mice. Very recently
we were able to show that within 9 days following peroral
infection with a low-dose (i.e., 1 cyst) of T. gondii, mice
harboring a human gut microbiota develop non-lethal subacute
ileitis characterized by increased T cell-dependent gut epithelial
apoptosis and pro-inflammatory cytokine secretion in intestinal
and extra-intestinal compartments (20). Furthermore, low-dose
T. gondii infected mice displayed rather mild-to-moderate
histopathological changes of the ileal mucosa and lamina propria,
whereas no transmural small intestinal necrosis like in the lethal
high-dose infection model could be observed. In the present
preclinical intervention study we assessed whether therapeutic
PACAP application starting 3 days after ileitis induction (i)
resulted in disease-alleviating effects in the intestinal tract, (ii)
was associated with distinct shifts in gut microbiota composition,
and furthermore, (iii) whether potential PACAP-induced anti-
inflammatory effect could also be observed in extra-intestinal
organs or (iv) even in systemic compartments.
MATERIALS AND METHODS
Generation of Mice With a Human Gut
Microbiota by Fecal Microbiota
Transplantation
Female C57BL/6j mice were raised andmaintained under specific
pathogen-free (SPF) conditions in the Forschungseinrichtungen
für Experimentelle Medizin (FEM, Charité - University
Medicine, Berlin, Germany). Mice with a depleted microbiota
(i.e., secondary abiotic mice) were generated as reported
earlier (15, 18). Briefly, eight-week-old mice were kept in
autoclaved cages and treated with an antibiotic cocktail
for 8 weeks containing ampicillin plus sulbactam (1 g/L;
Ratiopharm, Germany), vancomycin (500 mg/L; Cell Pharm,
Germany), ciprofloxacin (200 mg/L; Bayer Vital, Germany),
imipenem (250 mg/L; MSD, Germany) and metronidazole (1
g/L; Fresenius, Germany) (ad libitum). Successful depletion
of the gut microbiota was confirmed in fecal samples by both,
culture and molecular (16S rRNA based) methods as stated
elsewhere (18, 21). In order to guarantee antibiotic washout, the
antibiotic cocktail was replaced by sterile tap water (ad libitum)
3 days before human fecal microbiota transplantation (FMT).
Fresh fecal samples that were negative for enteropathogenic
bacteria, viruses, and parasites were donated from five healthy
human individuals, dissolved in sterile phosphate buffered saline
(PBS; Gibco, Life Technologies, United Kingdom) and stored
Abbreviations: CFU, colony forming units; DSS, dextran sodium sulfate; FMT,
fecal microbiota transplantation; H&E, hematoxylin and eosin; Hma, human
microbiota associated; HPF, high power field; IBD, inflammatory bowel disease;
IFN, interferon; IL, interleukin; i.p., intraperitoneal; MLN, mesenteric lymph
nodes; PACAP, Pituitary adenylate cyclase-activating polypeptide; PBS, phosphate
buffered saline; p.i., post-infection; PLC, placebo; qRT-PCR, quantitative real-time
polymerase chain reaction; SPF, specific pathogen free; Th, T helper cell; TNF,
tumor necrosis factor; VIP, vasoactive intestinal peptide.
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at−80◦C until usage as described previously (18). Immediately
before FMT, individual fecal aliquots were thawed, pooled and
applied to secondary abiotic mice by gavage on three consecutive
days (18). Between individual FMT challenges, bacterial loads
varied <0.5 orders of magnitude (Figure S1). For appropriate
establishment of the complex human gut microbiota within
the murine host, mice were kept for 12 days before subacute
ileitis induction. Immediately before peroral T. gondii infection
(d0) and at the end of the observation period [i.e., day 9
post-infection (p.i.)] individual fecal samples were collected
from human microbiota associated (hma) mice for subsequent
quantification of the main gut bacterial groups by molecular
methods as described elsewhere (15, 18, 19).
Induction of Subacute Ileitis,
Determination of Parasitic Loads
For induction of subacute ileitis, hma mice were perorally
challenged with one cyst of T. gondii strain ME49 in 0.3mL brain
suspension by gavage as reported earlier (20). T gondii DNA was
quantitated in ileal ex vivo biopsies as stated previously (16).
Treatment
PACAP38 was synthesized at the Department of Medical
Chemistry, University of Szeged (Hungary) and applied to mice
with a daily dose of 1.5mg per kg body weight (in PBS) (9, 17).
Mice received either the synthetic PACAP38 or PBS as placebo
control (PLC) via the intraperitoneal (i.p.) route (0.3mL) from
day 3 p.i. until day 8 p.i. once daily.
Clinical Conditions and Sampling
Procedures
Clinical conditions of mice including body weight loss were
monitored daily. Nine days post ileitis induction mice were
sacrificed by isoflurane treatment (Abbott, Germany). Cardiac
blood and ex vivo biopsies were derived from mesenteric
lymph nodes (MLN), lung, liver, ileum and colon under aseptic
conditions. Respective tissue samples were taken from each
mouse in parallel for immunological, immunohistochemical, and
microbiological analyses. Whereas the small intestinal lengths
were assessed by measuring the distance from the duodenum
leaving the stomach to the ileal-cecal valve, the colonic lengths
were measured from the ileal-cecal valve to the rectum with a
ruler and expressed in cm.
Histopathology and Immunohistochemistry
Ex vivo biopsies were derived from the terminal ileum, colon,
lung, and liver, fixed in 5% formalin and embedded in paraffin.
Histopathological changes were quantitated in 5µm thin, with
hematoxylin and eosin (H&E) stained ileal paraffin sections
applying a standardized histopathological scoring system ranging
from 0 to 6 as stated elsewhere (15).
Paraffin sections (5µm) were further analyzed applying
in situ immunohistochemistry as reported previously (22).
Briefly, in order to quantitate apoptotic cells and T lymphocytes,
primary antibodies against cleaved caspase-3 (Asp175, #9661,
Cell Signaling, Leiden, Netherlands; 1:200), and CD3 (#IR50361-
2, Dako, Santa Clara, CA, USA; 1:5) were applied, respectively.
The average number of positively stained cells (within at least
six high power fields (HPF), 0.287 mm2, 400x magnification) was
assessed by an independent and blinded investigator.
Pro-inflammatory Cytokine Secretion
Ileal and colonic tissue samples (∼1 cm2) were cut longitudinally
and washed in PBS. Respective intestinal ex vivo biopsies as
well as samples derived from MLN (3 lymph nodes), liver
samples (∼1 cm2) and lung were placed in 24-flat-bottom well-
culture plates (Falcon, Germany) supplemented with 500µL
serum-free RPMI 1640 medium (Gibco, life technologies),
penicillin (100 U/mL, Biochrom, Germany) and streptomycin
(100µg/mL; Biochrom). After overnight incubation at 37◦C,
culture supernatants were taken and tested for IL-6, TNF, and
IFN-γ secretion applying the Mouse Inflammation Cytometric
Bead Assay (CBA; BD Bioscience) on a BD FACSCanto II flow
cytometer (BD Bioscience). Systemic pro-inflammatory cytokine
concentrations were measured in serum samples.
Molecular Analysis of the Human Fecal
Donor Suspensions and the Intestinal
Microbiota
Human fecal donor suspensions as well as fresh ileal and
colonic luminal samples were immediately transferred to liquid
nitrogen and stored at −80◦C until further analyses. Fecal
DNA extraction was performed as reported earlier (15). Briefly,
the amount of DNA was assessed with a Quant-iT PicoGreen
reagent (Invitrogen, UK) and adjusted to 1 ng per µL. The
main human gut bacterial groups including enterobacteria,
enterococci, lactobacilli, bifidobacteria, Bacteroides/Prevotella
species, Clostridium coccoides group, and Clostridium leptum
group as well as the total eubacterial loads were determined
applying quantitative real-time polymerase chain reaction (qRT-
PCR) and species-, genera- or group-specific 16S rRNA gene
primers (Tib MolBiol, Germany) as indicated (Figure S2) and
further described previously (19, 23) (expressed as 16S rRNA
gene copies per ng DNA).
Bacterial Translocation
In order to survey viable bacteria translocating from the
gastrointestinal tract to extra-intestinal including systemic tissue
sites, ex vivo biopsies were taken from MLN, lungs, and liver,
homogenized in sterile PBS and analyzed in serial dilutions
on defined solid culture media as reported previously (15, 24).
Cardiac blood was incubated in thioglycolate enrichment broths
(BD Bioscience, Germany) for at least 7 days at 37◦C and
then streaked on culture media (25, 26). For at least 2 days
bacteria were grown under aerobic, microaerobic and anaerobic
conditions at 37◦C.
Statistical Analysis
Medians and levels of significance were determined by the
one-way ANOVA test followed by Tukey post-correction test
for multiple comparisons. Two-sided probability (p) values
≤0.05 were considered significant. Experiments were reproduced
three times.
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FIGURE 1 | Macroscopic effects in PACAP treated mice with a human gut microbiota suffering from subacute ileitis. Subacute ileitis was induced by T. gondii infection
of mice harboring a human gut microbiota (day 0). Starting 3 days post-infection (p.i.), mice were either treated with PACAP or placebo (PLC). Uninfected mice with a
human microbiota served as control animals (Naive). At day 9 p.i., (A) relative body weight loss, (B) small intestinal, and (C) large intestinal lengths were assessed. Box
plots represent the 75 and 25th percentiles of the median (black bar inside the boxes). The total range and significance levels determined by one-way ANOVA test
followed by Tukey post-correction test for multiple comparisons are shown. Total numbers of analyzed animals are given in parentheses. Data were pooled from four
independent experiments.
RESULTS
Macroscopic Sequelae in PACAP Treated
Mice With a Human Gut Microbiota
Suffering From Subacute Ileitis
In the present preclinical intervention study we addressed
whether therapeutic application of synthetic PACAP dampened
pro-inflammatory responses in intestinal and extra-intestinal
including systemic compartments of mice with a human gut
microbiota suffering from subacute ileitis. The small intestinal
immunopathology was induced by peroral low dose T. gondii
infection on day 0 (20). Three days post ileitis induction,
hma mice were treated with synthetic PACAP for 6 days
in total and clinical conditions including the body weights
were monitored. Remarkably, T. gondii infected placebo (PLC)
control mice exhibited substantial body weight loss until day
9 p.i., whereas this was not the case in PACAP treated mice
(Figure 1A). Given that intestinal inflammation is accompanied
by a significant shortening of the inflamed intestine (15, 18, 27),
we measured small intestinal lengths upon necropsy. At day 9
p.i., PACAP treatedmice displayed slightly longer small intestines
as compared to PLC control animals (Figure 1B). Of note, the
standard deviation within the PLC group was relatively high,
which might explain the non-significant differences compared
to the naive cohort (Figure 1B). Even though the terminal
ileum is well-known to be the predilection site of T. gondii
induced immunopathology (14), we also assessed the lengths of
the large intestines. Interestingly, PLC, but not PACAP treated
mice displayed significantly shorter large intestines at day 9
p.i. as compared to naive mice (Figure 1C), pointing toward
inflammatory responses beyond the terminal small intestine,
additionally affecting the large intestinal tract. Hence, PACAP
treatment resulted in a better clinical / macroscopic outcome
of T. gondii induced subacute ileitis. To rule out that the
observed differences in disease outcomes might be due to
different T. gondii infection efficiencies, we assessed parasitic
DNA concentrations in ileal ex vivo biopsies at day 9 p.i., but
detected comparable ileal T. gondii loads in mice of the PACAP
and PLC cohort (not shown).
Intestinal Anti-inflammatory Effects in
PACAP Treated Mice With a Human Gut
Microbiota Suffering From Subacute Ileitis
We next addressed PACAP-induced anti-inflammatory effects
in the intestinal tract on microscopic level. At day 9 following
ileitis induction ileal histopathological scores were lower in
PACAP treated hma mice as compared to PLC control
animals (Figure 2). Of note, we could not observe significant
differences in histopathological changes in the mucosa and
lamina propria of H&E stained colonic paraffin sections (not
shown). Since apoptosis is regarded a reliable parameter for the
histopathological grading of intestinal inflammation (16), we
further assessed T. gondii induced apoptotic cell responses in
the intestines by quantification of caspase3+ intestinal epithelial
cells applying in situ immunohistochemistry. At day 9 p.i., hma
mice displayed multifold increased numbers of apoptotic ileal
epithelial cells (Figure 3A). These increases were, however, less
pronounced in PACAP treated mice (Figure 3A; Figure S3A).
Given that T lymphocytes are the major driving forces of T.
gondii induced ileitis (14), we additionally stained ileal paraffin
sections with CD3 antibodies. Ileitis induction was, in fact,
accompanied by a marked increase in CD3+ ileal epithelial
cell numbers until day 9 p.i. (Figure 3B, Figure S3B), but to a
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FIGURE 2 | Microscopic effects in PACAP treated mice with a human gut
microbiota suffering from subacute ileitis. Subacute ileitis was induced by T.
gondii infection of mice harboring a human gut microbiota (day 0). Starting 3
days post-infection (p.i.), mice were either treated with PACAP or placebo
(PLC). Uninfected mice with a human microbiota served as control animals
(Naive). At day 9 p.i., histopathological changes within the ileum were
quantitated in H&E stained ileal paraffin sections applying a standardized
histopathological scoring system (left). Box plots represent the 75 and 25th
percentiles of the median (black bar inside the boxes). The total range and
significance levels determined by one-way ANOVA test followed by Tukey
post-correction test for multiple comparisons are shown. Total numbers of
analyzed animals are given in parentheses. Data were pooled from four
independent experiments. Histopathological changes are illustrated in
photomicrographs representative for four independent experiments (right;
100x magnification, scale bar 100µm).
significantly lesser extent upon PACAP treatment (Figure 3B,
Figure S3B). Remarkably, T. gondii-induced increases in both,
caspase3+ and CD3+ cells could also be observed in the epithelia
and mucosa / lamina propria of the large intestines, respectively
(Figures 3C,D, Figures S3C,D). Like in the ileal compartment,
PACAP treatment was accompanied with significantly less
distinct apoptosis and abundance of T lymphocytes in the large
intestinal tract (Figures 3C,D, Figures S3C,D).
We further assessed pro-inflammatory cytokine secretion in
intestinal ex vivo biopsies. At day 9 p.i., PLC, but not PACAP
treated mice exhibited higher IL-6 concentrations in their ileum
as compared to naive counterparts (Figure 4A). In addition, TNF
secretion was far less pronounced in the ileum and MLN of mice
from the PACAP cohort as compared to PLC control animals
(Figures 4B,C). Hence, PACAP exerts potent inflammation-
alleviating effects in the intestinal tract of hma mice during
subacute ileitis that are not restricted to the terminal ileum.
Changes in Gut Microbiota Composition in
PACAP Treated Mice With a Human Gut
Microbiota Suffering From Subacute Ileitis
Given that intestinal inflammatory conditions are accompanied
by shifts in commensal gut microbiota composition of mice
FIGURE 3 | Apoptotic epithelial cell and T lymphocyte responses in the
intestinal tract following PACAP treatment of mice with a human gut microbiota
suffering from subacute ileitis. Subacute ileitis was induced by T. gondii
infection of mice harboring a human gut microbiota (day 0). Starting 3 days
post-infection (p.i.), mice were either treated with PACAP or placebo (PLC).
Uninfected mice with a human microbiota served as control animals (Naive). At
day 9 p.i., the average numbers of apoptotic epithelial cells [Casp3+; (A,C)]
and of T lymphocytes [CD3+; (B,D)] in at least six high power fields (HPF)
were quantitatively assessed in ileal (A,B) and colonic (C,D) paraffin sections
applying in situ immunhistochemistry. Box plots represent the 75 and 25th
percentiles of the median (black bar inside the boxes). The total range and
significance levels determined by one-way ANOVA test followed by Tukey
post-correction test for multiple comparisons are shown. Total numbers of
analyzed animals are given in parentheses. Data were pooled from four
independent experiments.
and men termed dysbiosis (15, 19, 26, 28–30), we quantitatively
surveyed the main gut bacterial groups during subacute
ileitis development in PACAP and PLC treated mice applying
culture-independent 16S rRNA based methods (Figures 5A-H).
Irrespective of the treatment regimen, the total eubacterial loads
in the ileal lumen slightly declined until day 9 p.i. (Figure 5A).
Conversely, ileitis development was accompanied by higher gene
numbers of enterobacteria and enterococci in the ilea of PLC, but
not PACAP mice (Figures 5B,C), whereas lactobacilli loads were
higher in PACAP treated mice at day 9 p.i. as compared to both,
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FIGURE 4 | Intestinal pro-inflammatory cytokine secretion upon PACAP treatment of mice with a human gut microbiota suffering from subacute ileitis. Subacute ileitis
was induced by T. gondii infection of mice harboring a human gut microbiota (day 0). Starting 3 days post-infection (p.i.), mice were either treated with PACAP or
placebo (PLC). Uninfected mice with a human microbiota served as control animals (Naive). At day 9 p.i., secretion of pro-inflammatory cytokines such as IL-6 (A) and
TNF (B,C) were assessed in ex vivo biopsies derived from the ileum (A,B) and from mesenteric lymph nodes [MLN; (C)]. Box plots represent the 75 and 25th
percentiles of the median (black bar inside the boxes). The total range and significance levels determined by one-way ANOVA test followed by Tukey post-correction
test for multiple comparisons are shown. Total numbers of analyzed animals are given in parentheses. Data were pooled from four independent experiments.
T. gondii infected PLC treated mice and naive control animals
(Figure 5D). Remarkably, bifidobacteria were only marginally
abundant in mice suffering from subacute ileitis (Figure 5E),
with a trend toward higher loads in PACAP vs. PLC mice
at day 9 p.i. (Figure 5E). Furthermore, Clostridium coccoides
gene numbers were lower in the ileum derived from T. gondii
infected mice of either cohort (Figure 5G), whereas this was the
case for Clostridium leptum in PLC mice (Figure 5H), but not
PACAP treated counterparts (Figure 5H). Hence, subacute ileitis
development in hma mice was accompanied with distinct shifts
in the microbiota composition of the inflamed ileum, but to a
lesser extent upon PACAP treatment.
Extra-intestinal Anti-inflammatory Effects
in PACAP Treated Mice With a Human Gut
Microbiota Suffering From Subacute Ileitis
We next addressed whether anti-inflammatory effects upon
PACAP treatment of hma mice with subacute ileitis were
restricted to the intestinal tract or might also be observed in
extra-intestinal including systemic compartments. Nine days
following ileitis induction multi-fold increased numbers of
apoptotic cell numbers could be observed in the livers derived
from PLC and PACAP treated mice as compared to naive
animals (Figure 6A; Figure S4A), but with lower counts in
the latter as compared to the former (Figure 6A; Figure S4A).
Irrespective of the treatment regimen, increases in apoptotic
hepatic cell numbers were paralleled by more than three-fold
higher numbers of T lymphocytes in the livers of T. gondii
infected as compared to naive mice (Figure 6B; Figure S4B).
Furthermore, multi-fold elevated numbers of both apoptotic
cells and T lymphocytes could be assessed in the lungs during
subacute ileitis (Figures 6C,D; Figures S4C,D), but with lower
counts in PACAP as compared to PLC treated mice at day 9 p.i.
(Figures 6C,D; Figures S4C,D).
We next measured pro-inflammatory cytokine secretion
in ex vivo biopsies derived from respective extra-intestinal
compartments and detected less distinctly increased INF-γ
concentrations in the liver and lungs of PACAP as compared
to PLC treated mice at day 9 p.i. (Figure 7). As for the ileum,
subacute ileitis induction was further accompanied by elevated
systemic concentrations of pro-inflammatory cytokines such as
TNF and IL-6 (Figure 8). Strikingly, PACAP treatment resulted
in ∼50% lower TNF and IL-6 concentrations measured in
serum samples taken at day 9 p.i. as compared to PLC control
mice (Figure 8). Hence, the profound anti-inflammatory effects
exerted by PACAP treatment of hma mice during subacute ileitis
were not restricted to the intestinal tract, but could also be
observed in extra-intestinal and even systemic compartments.
DISCUSSION
Several in vitro and in vivo studies revealed that PACAP exerts
its neuroprotective properties via immune-modulatory and
anti-apoptotic mechanisms (5, 6). Given its virtual ubiquitous
expression, however, PACAP rather acts as a pleiotropic
immune regulator and hence, also beyond the nervous system
(6, 31). In fact, our previous work revealed that synthetic
PACAP application starting prior acute ileitis induction (i.e.,
prophylactic regimen) ameliorated intestinal as well as extra-
intestinal sequelae of peroral high-dose T. gondii infection in a
time-of-treatment dependent manner (17) that is characterized
by a T cell-driven pro-inflammatory cytokine storm with fatal
outcome within 1 week (14, 15). In the present preclinical
intervention study we provide additional insights into the
inflammation-ameliorating properties of exogenous PACAP. The
here applied subacute infection model following peroral low-
dose T. gondii infection of mice with a human gut microbiota
has been established by our group very recently (20) and is
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FIGURE 5 | Colonic microbiota changes following PACAP treatment of mice with a human gut microbiota suffering from subacute ileitis. Subacute ileitis was induced
by T. gondii infection of mice harboring a human gut microbiota (day 0). Starting 3 days post-infection (p.i.), mice were either treated with PACAP or placebo (PLC).
Uninfected mice with a human microbiota served as control animals (Naive). At day 9 p.i., the microbiota composition of the ileal lumen (A-H) was determined by
quantitative Real-Time PCR amplifying bacterial 16S rRNA variable regions of the main intestinal bacterial groups (expressed as 16S rRNA gene numbers per ng DNA)
including the total eubacterial load as indicated. Box plots represent the 75 and 25th percentiles of the median (black bar inside the boxes). The total range and
significance levels determined by one-way ANOVA test followed by Tukey post-correction test for multiple comparisons are shown. Total numbers of analyzed animals
are given in parentheses. Data were pooled from four independent experiments.
characterized by a non-lethal, far less acute course of small
intestinal inflammation (as compared to high-dose T. gondii
infection), and importantly, mimics human gut microbiota
conditions. The low-dose T. gondii infection model of hma
mice thus provides valuable opportunities to further dissect
the molecular mechanisms underlying the interactions between
pathogen, host immunity, and human gut microbiota during
small intestinal inflammation (20).
In our present work we demonstrate that PACAP applied
in a therapeutic regimen (starting post ileitis induction) exerts
anti-inflammatory effects during subacute ileitis of (with respect
to their gut microbiota) “humanized” mice as indicated by (1)
better clinical / macroscopic conditions (including lack of body
weight loss and of shrinkage of the intestinal lengths during ileitis
development), (2) less distinct histopathological changes in the
terminal ileum, (3) lower numbers of apoptotic epithelial cells
and of T lymphocytes in both, ileum and colon, (4) less intestinal
secretion of pro-inflammatory cytokines such as TNF and IL-
6, (5) less apoptosis in extra-intestinal organs such as liver and
lungs that is accompanied by (6) lower pulmonal T cell numbers,
and (7) less IFN-γ secretion in liver and lungs, and, remarkably,
(8) lower systemic concentrations of pro-inflammatory cytokines
such as TNF and IL-6. Furthermore, (9) inflammation-associated
gut microbiota shifts were less pronounced following PACAP as
compared to PLC treatment.
The potent anti-inflammatory effects of exogenous PACAP
within the intestinal tract as assessed in our actual and
previous (17) study are further supported by two previous
reports demonstrating that PACAP−/− mice were suffering
from more severe DSS-induced colitis as compared to wildtype
counterparts (9, 10). When synthetic PACAP was applied via
the intraperitoneal route, however, the inflammatory phenotype
could be alleviated (9).
Even though peroral T. gondii infection of susceptible mice
is known to primarily affect the terminal ileum, we extended
our focus to the large intestines here. We did indeed observe
marked T. gondii induced colonic inflammatory responses
as indicated by multi-fold increased numbers of apoptotic
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FIGURE 6 | Apoptotic epithelial cell and T lymphocyte responses in
extra-intestinal compartments following PACAP treatment of mice with a
human gut microbiota suffering from subacute ileitis. Subacute ileitis was
induced by T. gondii infection of mice harboring a human gut microbiota (day
0). Starting 3 days post-infection (p.i.), mice were either treated with PACAP or
placebo (PLC). Uninfected mice with a human microbiota served as control
animals (Naive). At day 9 p.i., the average numbers of apoptotic epithelial cells
[Casp3+; (A,C)] and of T lymphocytes [CD3+; (B,D)] in at least six high power
fields (HPF) were quantitatively assessed in paraffin sections of ex vivo biopsies
derived from liver (A,B) and lung (C,D) applying in situ immunhistochemistry.
Box plots represent the 75 and 25th percentiles of the median (black bar
inside the boxes). The total range and significance levels determined by
one-way ANOVA test followed by Tukey post-correction test for multiple
comparisons are shown. Total numbers of analyzed animals are given in
parentheses. Data were pooled from four independent experiments.
colonic epithelial cells that could be effectively lowered by
therapeutic PACAP application, which also held true for T
lymphocytes within the colonic mucosa and lamina propria.
In previous in vitro studies PACAP was shown to inhibit
proliferation and migration of T lymphocytes and associated
pro-inflammatory cytokine release (3, 32). An in vivo study
further revealed that PACAP treated mice suffering from acute
peritonitis displayed a diminished influx of lymphocytes into the
peritoneal cavity (33).
Interestingly, synthetic PACAP was not sufficient to lower
T. gondii induced colonic pro-inflammatory cytokine secretion
(not shown), whereas this was the case in ex vivo biopsies
FIGURE 7 | Extra-intestinal pro-inflammatory cytokine responses following
PACAP treatment of mice with a human gut microbiota suffering from
subacute ileitis. Subacute ileitis was induced by T. gondii infection of mice
harboring a human gut microbiota (day 0). Starting 3 days post-infection (p.i.),
mice were either treated with PACAP or placebo (PLC). Uninfected mice with a
human microbiota served as control animals (Naive). At day 9 p.i., IFN-γ
secretion was assessed in ex vivo biopsies derived from the liver (A) and from
lung (B). Box plots represent the 75 and 25th percentiles of the median (black
bar inside the boxes). The total range and significance levels determined by
one-way ANOVA test followed by Tukey post-correction test for multiple
comparisons are shown. Total numbers of analyzed animals are given in
parentheses. Data were pooled from four independent experiments.
FIGURE 8 | Systemic pro-inflammatory cytokine responses following PACAP
treatment of mice with a human gut microbiota suffering from subacute ileitis.
Subacute ileitis was induced by T. gondii infection of mice harboring a human
gut microbiota (day 0). Starting 3 days post-infection (p.i.), mice were either
treated with PACAP or placebo (PLC). Uninfected mice with a human
microbiota served as control animals (Naive). At day 9 p.i., secretion of
pro-inflammatory cytokines such as TNF (A) and IL-6 (B) were measured in
serum samples. Box plots represent the 75 and 25th percentiles of the median
(black bar inside the boxes). The total range and significance levels determined
by one-way ANOVA test followed by Tukey post-correction test for multiple
comparisons are shown. Total numbers of analyzed animals are given in
parentheses. Data were pooled from four independent experiments.
derived from the ileum and fromMLN. Our present observations
are supported by our previous reports in both acute (25, 26)
and subacute (20) murine ileitis further emphasizing that T.
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gondii induced immunopathology does not exclusively affect the
terminal ileum, but might also affect the large intestines.
The well-known anti-apoptotic properties of PACAP were
not restricted to the intestinal tract, but could also be assessed
in extra-intestinal organs such as the liver and lungs and were
paralleled by decreased IFN-γ secretion in respective organs.
In line, PACAP could exert potent protective effects in human
hepatocytes in vitro and in a murine model of liver ischemia
and oxidative stress (34, 35) as well as in endotoxin-induced
acute lung inflammation (36). Notably, synthetic PACAP analogs
have been developed for the treatment of bronchial asthma given
the anti-inflammatory and broncho-relaxant properties of the
neuropeptide (36, 37).
We further addressed whether the observed inflammation-
alleviating responses in PACAP treated mice were paralleled
by less translocation of viable bacteria originating from
the commensal gut microbiota to extra-intestinal including
systemic compartments due to less distinct epithelial barrier
damage. It is well-known that during acute ileitis bacterial
commensals including Escherichia coli overgrowing the ileal
lumen might migrate through the compromised intestinal
epithelial barrier (i.e., “leaky gut”), come in close contact to
immune cells residing in the lamina propria which might
subsequently result in an exacerbation of the inflammatory
immune responses (38–40). Interestingly, in our actual
study bacteria could neither be cultured from MLN, nor
from extra-intestinal compartments including liver, lungs
and cardiac blood. Our recent study, however, revealed
that mean commensal bacterial translocation rates of more
than 80% could be assessed in liver and lungs during lethal
acute ileitis (25, 26).
One might argue that the better outcome observed in
PACAP treated hma mice with T. gondii induced ileitis
was due to direct anti-microbial effects of the applied
synthetic compound, given that both anti-parasitic (directed
against Trypanosoma brucei) (41) and anti-bacterial (42)
effects have been reported recently. In both our previous
and actual studies we could, however, exclude any anti-
microbial effects of the working solutions containing synthetic
PACAP in vitro (17). Furthermore, the start of exogenous
PACAP 3 days after T. gondii infection, in addition to
comparable parasitic DNA loads as assessed in ileal ex vivo
biopsies argue against a biological relevant anti-microbial
effect of PACAP.
Meanwhile it is well-established that the orchestrated
mutualistic microbiota-host relationships are of utmost
importance for host cell physiology, immune homeostasis
and resistance to disease (21, 43). Perturbations within the
complex microbial ecosystem in the gastrointestinal tract are
associated with increased susceptibility of the host to distinct
intestinal morbidities including IBD, irritable bowel syndrome
and coeliac disease (21, 44, 45). Likewise, intestinal inflammatory
conditions are paralleled by shifts in the intestinal microbiota
composition (15, 25, 26, 28–30, 46, 47). This phenomenon
could also be observed in our actual survey of the microbiota
composition within the inflamed ileal lumen, given that
subacute ileitis development was associated with increases in
enterobacteria (including E. coli) and enterococci, whereas
obligate anaerobic Clostridium coccoides and Clostridium leptum
gene numbers decreased until day 9 p.i. These microbiota
shifts are supported by our previous results obtained from
lethal acute ileitis of mice, but with a conventional (i.e.,
murine) gut microbiota (15, 46, 47). Remarkably, neither
shifts toward increased enterobacteria and enterococci,
nor to decreased numbers of Clostridium leptum could be
assessed in the ilea of PACAP treated mice. Furthermore,
PACAP treatment was associated with higher abundances of
(potentially probiotic) lactobacilli that had been reduced during
acute ileitis (15).
Interestingly, PACAP could inhibit TLR-4 activation
in a model of traumatic brain injury (48). Given that T.
gondii induced ileitis is initiated and further worsened by
TLR-4 dependent signaling of bacterial LPS originating
from the cell walls of Gram-negative commensals
including enterobacteria such as E. coli accumulating in
the inflamed ileal lumen (46, 47), alleviation of the TLR-
4 dependent scenario constitutes a mechanistic corner
stone of the multi-facetted “health-beneficial actions” of
PACAP treatment.
Strikingly, exogenous PACAP could not only sufficiently
dampen ileal, but also serum TNF and IL-6 concentrations,
pointing toward potent systemic anti-inflammatory properties
of the synthetic compound, which could also be observed in
lethal acute ileitis (17). These systemic effects of exogenous
PACAP are supported by several studies where PACAP could
efficiently prevent from experimental endotoxin sepsis and
shock (49–51).
Given the time-of-treatment dependent anti-inflammatory
effect of exogenous PACAP observed during acute ileitis (17),
one might further argue that starting PACAP application to
hma mice before subacute ileitis induction (i.e., prophylactic
regimen) might yield even more pronounced anti-apoptotic
and anti-inflammatory effects in intestinal and extra-intestinal
including systemic compartments. This should be addressed in
future studies.
In summary, our preclinical intervention study provides
strong evidence that synthetic PACAP alleviates subacute
ileitis and extra-intestinal including systemic sequelae of T
cell-driven immunopathology. We conclude that synthetic
PACAP might open novel options for the (adjunct) therapy
and/or prophylaxis of intestinal inflammation including IBD
and further supports the pathophysiological role of the gut-
brain axis.
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Figure S1 | Microbiota composition of human donor feces. Before human FMT of
secondary abiotic mice on 3 consecutive days, the main gut bacterial groups were
quantitated in human fecal donor suspensions. Applying quantitative RT-PCR
analysis, the 16S rRNA of the main gut commensal species such as
enterobacteria (EB), enterococci (EC), lactobacilli (LB), bifidobacteria (Bif),
Bacteroides / Prevotella species (B/P), Clostridium coccoides group (Clocc),
Clostridium leptum group (Clept), as well as the total eubacterial load (TL) were
assessed (gene numbers per ng DNA). The shown data are representative for four
independent experiments. Total range as well as box plots representing the 75
and 25th percentiles of the median (black bar inside the boxes) are shown.
Figure S2 | Primer sequences for molecular gut microbiota analyses.
Figure S3 | Representative photomicrographs illustrating apoptotic epithelial cell
and T lymphocyte responses in the intestinal tract following PACAP treatment of
mice with a human gut microbiota suffering from subacute ileitis. Subacute ileitis
was induced by T. gondii infection of mice harboring a human gut microbiota (day
0). Starting 3 days post-infection (p.i.), mice were either treated with PACAP or
placebo (PLC). Uninfected mice with a human microbiota served as control
animals (Naive). Representative photomicrographs out of four independent
experiments illustrate the average numbers of apoptotic epithelial cells (Casp3+;
A,C) and of T lymphocytes [CD3+; (B,D)] in at least six high power fields (HPF) as
quantitatively assessed in ileal (A,B) and colonic (C,D) paraffin sections applying in
situ immunohistochemistry at day 9 p.i.
Figure S4 | Representative photomicrographs illustrating apoptotic cell and T
lymphocyte responses in extra-intestinal compartments following PACAP
treatment of mice with a human gut microbiota suffering from subacute ileitis.
Subacute ileitis was induced by T. gondii infection of mice harboring a human gut
microbiota (day 0). Starting 3 days post-infection (p.i.), mice were either treated
with PACAP or placebo (PLC). Uninfected mice with a human microbiota served as
control animals (Naive). Representative photomicrographs out of four independent
experiments illustrate the average numbers of apoptotic cells [Casp3+; (A,C)] and
of T lymphocytes [CD3+; (B,D)] in at least six high power fields (HPF) as
quantitatively assessed in paraffin sections of ex vivo biopsies derived from liver
(A,B) and lung (C,D) applying in situ immunohistochemistry at day 9 p.i.
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